Effectiveness of lurasidone in improving cognitive function in bipolar patients

(who currently have no mood symptoms)

PURPOSE OF THIS STUDY:

This study is looking at changes in cognitive function in bipolar patients who are treated with 20 to 80mg/day of Lurasidone vs Placebo adjunctive therapy over a 6 week period.

WHO CAN PARTICIPATE?

> Males and females between 19-65 years of age
> Have a diagnosis of Bipolar Disorder
> Are clinically stable on current medication
> Not currently in a manic or depressed episode

WHAT IS INVOLVED?

The study involves a screening visit, baseline visit, clinical visits at Weeks 3 and 6, and 4 telephone calls at Week 1, 2, 4 and 2 weeks after last visit. Participants will complete neurocognitive (eg: memory, reasoning and attention) testing and give blood samples. Participants with cognitive impairment will be randomly allocated, to either receive lurasidone or placebo added to their current medications for 6 weeks.

CONTACT INFORMATION:

Jayasree Basivireddy, Clinical Research Coordinator
Phone: 604.822.3769
Email: jayasree.basivireddy@ubc.ca

To learn more about this study, visit vchri.ca/participate

STUDY TIME/DURATION

From July 2016 to December 31, 2019

STUDY LOCATION

Outpatient Clinic,
Mood Disorders Centre,
Djavad Mowafaghian Centre for Brain Health
at UBC

PRINCIPAL INVESTIGATOR

Dr. Lakshmi N Yatham

Professor of Psychiatry, UBC

Regional Head, Department of Psychiatry

Regional Program Medical Director

Vancouver Coastal Health and Providence Health Care

Mental Health and Addictions

Health research changes lives.

Be part of the discovery.
vchri.ca/participate

Vancouver CoastalHealth Research Institute